- Dana-Farber and colleagues from the Cancer Genome Atlas (TCGA) Research Network identified novel mutations in a well-known cancer-causing pathway in lung adenocarcinoma, potentially identifying a greater number of patients with treatable mutations because many potent cancer drugs that target these mutations already exist. Additionally, these findings may expand the number of possible new therapeutic targets for this disease.
Tags: BasicResearch, LungCancer
- Research led by Bruce Spiegelman, PhD, and colleagues shows that adipsin, a cell signaling protein made by fat cells, plays a critical, previously unsuspected role in stimulating insulin secretion to control blood sugar, and the discovery could have implications for treatment of type 2 diabetes.
- Dana-Farber Cancer Institute is acquiring the Commonwealth Hematology-Oncology (CHO) physician practice and extending its sophisticated cancer care model further into the community, effective July 1, 2014.
- Researchers at Dana-Farber and Brigham and Women's Hospital (BWH) have utilized nanomedicine technologies to develop a drug-delivery system that can precisely target and attack cancer cells in the bone, as well as increase bone strength and volume to prevent bone cancer progression.
Tags: BasicResearch, MultipleMyeloma
- Dana-Farber Cancer Institute and its Belfer Institute for Applied Cancer Science are collaborating with Johnson & Johnson Innovation, Boston and Janssen Biotech, Inc., to identify which lung cancer patients would benefit from a new generation of immunotherapies and which combination of such therapies will be the most effective.
Tags: BasicResearch, LungCancer, Immunotherapy
- Dana-Farber Cancer Institute is opening its newest satellite location for hematology and oncology services at St. Elizabeth's Medical Center in Brighton, Massachusetts.
- Scientists have redoubled efforts to disable the mutated cancer gene KRAS, which confers an especially poor prognosis and has proved extraordinarily difficult to target. New research has identified an additional hurdle: inhibiting KRAS can activate a backup pathway in cancer cells that enables them to survive and thrive in the oncogene's absence.
Tags: BasicResearch, Genomics
- Boston Mayor Martin Walsh reflected on his successful fight against childhood lymphoma at Dana-Farber’s annual celebration of survivorship. He was diagnosed at age 7 with Burkitt’s lymphoma, a rare, aggressive form of non-Hodgkin lymphoma that primarily affects children.
Tags: ChildhoodCancer, Survivorship
- Dana-Farber scientists report on a natural hormone that is increased by physical exercise and by exposure to cold improves blood sugar control, suppresses inflammation, and burns fat to mold leaner bodies in mice can be made in the laboratory and could have therapeutic potential for several diseases.
- Practice-changing clinical research conducted at the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology was featured at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session.
Tags: BreastCancer, ProstateCancer
Showing 11-20 of 520 items